Bisphosphonate use in the horse: what is good and what is not?
Authors: Mitchell Alexis, Watts Ashlee E, Ebetino Frank H, Suva Larry J
Journal: BMC veterinary research
Summary
# Editorial Summary: Bisphosphonate Use in the Horse Bisphosphonates represent a diverse drug class with two primary mechanisms of action: strong binding to bone mineral and potent inhibition of osteoclast-mediated bone resorption. Non-nitrogen-containing formulations disrupt osteoclast energy metabolism directly, whilst nitrogen-containing variants inhibit cholesterol biosynthesis and cellular signalling pathways, with the latter group demonstrating broader physiological effects including anti-angiogenic, anti-metastatic, and analgesic properties. Mitchell and colleagues conducted a comprehensive review of bisphosphonate pharmacology and clinical applications, synthesising evidence from both human and equine medicine to evaluate their therapeutic utility and safety profile. Beyond bone resorption inhibition, these agents modulate matrix metalloproteinase activity, cytokine expression, and growth factor signalling—mechanisms potentially valuable for managing equine conditions characterised by excessive bone loss or pathological remodelling. Whilst human clinical use has successfully transformed osteoporosis and cancer management, significant adverse events including acute-phase reactions, gastrointestinal inflammation, atypical fractures, and osteonecrosis of the jaw warrant cautious application in equine practice; practitioners must therefore weigh the potential benefits in conditions such as navicular disease and fracture healing against emerging safety concerns and the species-specific responses that remain incompletely understood.
Read the full abstract on PubMed
Practical Takeaways
- •Bisphosphonates offer potential therapeutic benefits for equine bone resorption diseases and pain management through multiple biological pathways beyond simple osteoclast inhibition
- •Practitioners must weigh therapeutic benefits against known adverse effects in humans; careful patient selection and monitoring protocols are essential when considering BP use in horses
- •Further equine-specific safety and efficacy data needed before recommending routine clinical use; current evidence is primarily derived from human and in vitro studies
Key Findings
- •Bisphosphonates inhibit osteoclast function through two mechanisms: non-nitrogen-containing BPs cause osteoclast apoptosis via energy metabolism disruption, while nitrogen-containing BPs inhibit cholesterol biosynthesis affecting intracellular signaling
- •Beyond bone resorption inhibition, BPs demonstrate activity against cancer cell metastases and proliferation, inhibit angiogenesis and matrix metalloproteinase activity, and modulate cytokine and growth factor expression
- •Human clinical use of BPs has transformed treatment of post-menopausal osteoporosis and metastatic cancers, but adverse events include acute-phase reactions, esophagitis, gastritis, atypical femoral fractures, and osteonecrosis of the jaw